VitaK owns IPR in the field of the conformation-specific testing of circulating MGP, and the use of MGP as a biomarker for cardiovascular disease. To third parties we offer interesting possibilities for licensing our patents

This patent family describes the use of MGP-related antigen as biomarker (tissue and circulating) for atherosclerosis, vascular disease, rheumatic arthritis, and angiogenesis. Also the measurement of MGP can be used to monitor drug or vitamin treatment.